Kyphoscoliotic Ehlers-Danlos syndrome
kai-foh-skoh-lee-ot-ik EHL-ers DAN-los sin-drohm
Also known as: kEDS, Ehlers-Danlos syndrome type VI
At a Glance
What is Kyphoscoliotic Ehlers-Danlos syndrome?
Kyphoscoliotic Ehlers-Danlos syndrome is a rare genetic disorder that affects connective tissues, which provide support to many parts of the body. The condition primarily impacts the musculoskeletal system, leading to severe curvature of the spine, known as kyphoscoliosis. It is caused by mutations in specific genes, such as PLOD1 or FKBP14, which affect collagen production. Over time, individuals may experience worsening joint instability, muscle weakness, and skin fragility. Early symptoms often include delayed motor development and hypotonia, while later symptoms can involve progressive scoliosis and respiratory issues. Early diagnosis is crucial to manage symptoms and prevent severe complications. The condition can significantly impact family life due to the need for ongoing medical care and potential physical limitations. Prognosis varies, but with proper management, individuals can lead fulfilling lives. Daily life may involve physical therapy, orthopedic interventions, and regular monitoring by healthcare professionals. Despite challenges, many affected individuals adapt well with supportive care. Emotional and psychological support is also important for both patients and their families.
Medical Definition
Kyphoscoliotic Ehlers-Danlos syndrome is characterized by a defect in collagen synthesis due to mutations in the PLOD1 or FKBP14 genes. Pathologically, this leads to a deficiency in lysyl hydroxylase, an enzyme critical for collagen cross-linking, resulting in weakened connective tissues. Histologically, affected tissues may show disorganized collagen fibrils and reduced tensile strength. The syndrome is classified under Ehlers-Danlos syndromes, specifically type VI, and is inherited in an autosomal recessive pattern. Epidemiologically, it is considered a rare disorder with a prevalence of approximately 1 in 100,000 to 1 in 200,000. The disease course involves progressive musculoskeletal deformities and potential cardiovascular complications, necessitating multidisciplinary management.
Kyphoscoliotic Ehlers-Danlos syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Joint hypermobility manifests as an unusually large range of movement in the joints, often leading to frequent dislocations and subluxations. This is caused by defects in collagen synthesis, which compromises the structural integrity of connective tissues. Over time, joint hypermobility can lead to chronic joint pain and early-onset osteoarthritis. It affects daily life by limiting physical activity and requiring physical therapy and bracing to manage symptoms.
Kyphoscoliosis presents as an abnormal curvature of the spine, combining kyphosis and scoliosis. It results from weakened connective tissues that fail to support the spine properly. As the condition progresses, it can lead to respiratory issues and chronic back pain. Daily life is impacted by reduced mobility and discomfort, often necessitating physical therapy and, in severe cases, surgical intervention.
Muscle hypotonia is characterized by decreased muscle tone, resulting in muscle weakness and delayed motor skills. This occurs due to the defective collagen affecting muscle fibers and connective tissue support. Over time, hypotonia can lead to difficulties in maintaining posture and performing physical activities. It affects daily life by causing fatigue and requiring physical therapy to improve muscle strength and coordination.
Common
Skin hyperextensibility is seen as skin that can be stretched beyond normal limits and returns to its original state. This is due to abnormal collagen production, which affects skin elasticity. Over time, the skin may become more prone to bruising and scarring. In daily life, individuals may need to take precautions to avoid skin injuries and use protective clothing.
Easy bruising occurs when minor trauma leads to significant bruising due to fragile blood vessels. This is caused by collagen defects that weaken the vascular walls. Over time, frequent bruising can lead to skin discoloration and discomfort. Daily life is affected by the need to avoid activities that could cause injury and the use of protective measures to prevent bruising.
Delayed motor development is observed as a lag in achieving motor milestones such as sitting, crawling, and walking. This delay is due to muscle hypotonia and joint instability affecting movement. Over time, children may catch up with peers but often require early intervention and physical therapy. It impacts daily life by necessitating additional support and therapy to improve motor skills.
Less Common
Arterial fragility is characterized by an increased risk of arterial rupture due to weakened vessel walls. This occurs because of defective collagen affecting the structural integrity of arteries. Over time, this can lead to life-threatening vascular complications. Daily life involves regular monitoring and avoiding activities that could increase blood pressure or cause trauma.
Hearing loss may present as a reduction in hearing ability, often due to conductive or sensorineural issues. This can be caused by collagen defects affecting the structures of the ear. Over time, hearing loss can progress, impacting communication and social interactions. Daily life may require the use of hearing aids and regular audiological assessments to manage the condition.
What Causes Kyphoscoliotic Ehlers-Danlos syndrome?
Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is primarily caused by mutations in the PLOD1 and FKBP14 genes, located on chromosomes 1p36.22 and 7p14.3, respectively. The PLOD1 gene encodes lysyl hydroxylase 1, an enzyme crucial for the hydroxylation of lysine residues in collagen, which is essential for the stability and function of collagen fibers. FKBP14 encodes FK506-binding protein 14, which is involved in protein folding and stabilization within the endoplasmic reticulum. Mutations in these genes lead to defective collagen synthesis and improper protein folding, resulting in structurally compromised collagen fibers. This molecular disruption affects the extracellular matrix, leading to weakened connective tissues and structural instability. Organelles such as the endoplasmic reticulum may experience stress due to the accumulation of misfolded proteins, triggering the unfolded protein response. This cellular stress can propagate to neighboring cells, exacerbating tissue fragility and contributing to the characteristic hypermobility and skin elasticity seen in kEDS. Neuroinflammation may be a secondary consequence, as the immune system responds to tissue damage and stress signals. Over time, these processes can lead to degeneration of white matter and other critical structures, impacting neurological function. Symptoms such as kyphoscoliosis, joint hypermobility, and skin hyperextensibility emerge due to the widespread impact of collagen defects across multiple organ systems. The variability in disease severity among patients can be attributed to the specific nature and location of the genetic mutations, as well as potential modifier genes and environmental factors. Additionally, the presence of vascular complications, as noted in some cases, may be linked to the degree of arterial fragility caused by compromised collagen integrity. Understanding the precise molecular mechanisms and pathways affected in kEDS is crucial for developing targeted therapies and management strategies. Further research is needed to elucidate the full spectrum of cellular and molecular consequences associated with these genetic mutations.
How is Kyphoscoliotic Ehlers-Danlos syndrome Diagnosed?
Typical age of diagnosis: Kyphoscoliotic Ehlers-Danlos syndrome is typically diagnosed in infancy or early childhood when symptoms such as joint hypermobility, skin hyperextensibility, and progressive kyphoscoliosis become apparent. Early diagnosis is crucial for managing complications and improving quality of life.
The clinician looks for characteristic features such as joint hypermobility, skin hyperextensibility, and progressive kyphoscoliosis. A detailed family history is important to identify any hereditary pattern. Physical examination findings include muscle hypotonia and delayed motor development. This step helps to differentiate kyphoscoliotic Ehlers-Danlos syndrome from other connective tissue disorders.
X-rays and MRI are commonly used imaging modalities. They reveal spinal deformities such as kyphosis and scoliosis, which are hallmark features of the syndrome. Imaging findings help confirm the diagnosis by visualizing the extent of spinal curvature. Differential diagnoses such as Marfan syndrome and osteogenesis imperfecta are excluded based on imaging characteristics.
Urine tests for lysyl hydroxylase activity are ordered to assess collagen synthesis. Biomarkers such as elevated hydroxylysine levels are sought. Abnormal results indicate defective collagen cross-linking, characteristic of the syndrome. These results guide the clinician to pursue genetic testing for confirmation.
Sequencing of the PLOD1 and FKBP14 genes is performed. Mutations such as missense or splice-site variants are found. Positive results confirm the diagnosis of kyphoscoliotic Ehlers-Danlos syndrome. Genetic findings inform family counseling regarding inheritance patterns and recurrence risks.
Kyphoscoliotic Ehlers-Danlos syndrome Treatment Options
Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used. They work by reducing inflammation and alleviating pain associated with joint and muscle strain. Specific drugs include ibuprofen and acetaminophen. Clinical evidence supports their efficacy in managing chronic pain symptoms. Limitations include gastrointestinal side effects and potential for long-term dependency.
Specific techniques include strengthening exercises and flexibility training. The therapeutic goals are to improve joint stability and enhance muscle strength. Sessions are typically conducted 2-3 times per week for several months. Measurable outcomes include increased range of motion and reduced pain levels. Long-term benefits include improved functional mobility and prevention of further joint damage.
Surgery is indicated for severe and progressive spinal deformities. The procedure involves fusing affected vertebrae to correct curvature and stabilize the spine. Expected benefits include reduced pain and prevention of further deformity progression. Surgical risks include infection, nerve damage, and blood loss. Post-operative care requires physical therapy and regular follow-up to monitor healing.
The care team includes geneticists, orthopedic specialists, physical therapists, and psychologists. Specific interventions focus on pain management, mobility improvement, and psychological support. Psychosocial support strategies include counseling and support groups. Family education involves teaching about disease management and genetic implications. Long-term monitoring includes regular assessments to manage complications and adjust treatment plans.
When to See a Doctor for Kyphoscoliotic Ehlers-Danlos syndrome
- Severe chest pain — this could indicate arterial fragility leading to a life-threatening vascular event.
- Sudden difficulty breathing — may signify a serious complication such as aortic rupture or pneumothorax.
- Loss of consciousness — could be due to a critical cardiovascular event requiring immediate medical intervention.
- Persistent joint pain — may indicate worsening joint instability; consult a specialist for management.
- Progressive scoliosis — requires monitoring and possibly intervention to prevent further complications.
- Frequent bruising — could suggest underlying vascular issues; seek medical advice for evaluation.
- Mild skin hyperextensibility — monitor for changes and maintain skin care to prevent injury.
- Occasional joint dislocations — ensure proper joint support and consult a physiotherapist for exercises.
Kyphoscoliotic Ehlers-Danlos syndrome — Frequently Asked Questions
Is this condition hereditary?
Kyphoscoliotic Ehlers-Danlos syndrome is inherited in an autosomal recessive pattern. This means both parents must carry one copy of the mutated gene for their child to be affected. De novo mutations are rare but can occur. Carriers typically do not show symptoms but can pass the gene to their offspring. Genetic counseling is recommended for affected families to understand inheritance risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the severity of symptoms and complications. Early onset of severe symptoms may worsen prognosis, while proper management can improve outcomes. Mortality is often related to vascular complications such as arterial rupture. Treatment and regular monitoring can significantly enhance survival and quality of life. Patients should have realistic expectations and work closely with healthcare providers.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often taking months to years due to symptom overlap with other conditions. Patients are typically seen by geneticists, orthopedists, and cardiologists. Delayed diagnosis is common due to misinterpretation of symptoms or lack of awareness. Genetic testing confirms the diagnosis by identifying mutations in PLOD1 or FKBP14 genes.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising studies focusing on gene therapy and novel pharmacological approaches. ClinicalTrials.gov is a valuable resource for finding relevant trials. Patients should discuss potential participation in trials with their doctors. New treatments may take years to become widely available, but ongoing research offers hope for future advancements. Staying informed about research developments is crucial for patients and families.
How does this condition affect daily life and activities?
Mobility and self-care can be significantly impacted, requiring adaptations and assistive devices. Educational settings may need to accommodate physical limitations and learning challenges. Social and emotional challenges include coping with chronic pain and potential isolation. The family burden can be substantial, necessitating support and resources. Access to physical therapy, counseling, and peer support groups can greatly assist in managing daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 20301635
- 2.FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 31132235
- 3.Kyphoscoliotic Ehlers-Danlos syndrome caused by pathogenic variants in FKBP14: Further insights into the phenotypic spectrum and pathogenic mechanisms.
Colman M, Vroman R, Dhooge T et al. · Hum Mutat · 2022 · PMID: 36054293
- 4.Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome.
Henneton P, Legrand A, Giunta C et al. · BMJ Case Rep · 2018 · PMID: 29982180
- 5.Vascular Phenotype of Kyphoscoliotic Ehlers-Danlos Syndrome.
Satapathy D, Venkatachari M · Indian J Pediatr · 2026 · PMID: 41507527
- 6.FKBP14 kyphoscoliotic Ehlers-Danlos syndrome misdiagnosed as Larsen syndrome: a case report.
Wiegand A, Kastury R, Neogi A et al. · Cold Spring Harb Mol Case Stud · 2023 · PMID: 37433679
- 7.FKBP14 kyphoscoliotic Ehlers-Danlos Syndrome in adolescent patient: the first Colombian report.
Ruiz-Botero F, Ramírez-Montaño D, Pachajoa H · Arch Argent Pediatr · 2019 · PMID: 31063316
- 8.Whole Blood Multi-OMIC Analysis Is Effective in Clinical Interpretation of Splicing Aberrations in PLOD1 -Related Kyphoscoliotic Ehlers-Danlos Syndrome.
Russo F, Daolio C, Di Muro E et al. · Am J Med Genet A · 2025 · PMID: 40205938
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-12